PPARG and metabolic dysfunction-associated steatotic liver disease: Extensive studies have substantiated that hepatic PPARγ induces the expression of lipid synthesis genes, thereby promoting hepatic lipid accumulation.44, 45, 46 Paradoxically, the clinical administration of PPARγ agonists for either short- or long-term treatment can ameliorate NAFLD.47